Assessment of futility in clinical trials

被引:77
作者
Snapinn, Steven [1 ]
Chen, Mon-Gy [1 ]
Jiang, Qi [1 ]
Koutsoukos, Tony [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
conditional power; predictive power; predictive probability; sequential analysis; stochastic curtailment;
D O I
10.1002/pst.216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 50 条
  • [21] Stochastically curtailed phase II clinical trials
    Ayanlowo, A. O.
    Redden, D. T.
    STATISTICS IN MEDICINE, 2007, 26 (07) : 1462 - 1472
  • [22] Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data
    Sambucini, Valeria
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (16)
  • [23] Futility for subgroup analyses in the adaptive signature design
    Callegaro, Andrea
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2019, 28 (03) : 953 - 961
  • [24] Evaluating futility of a binary clinical endpoint using early read-outs
    Van Lancker, Kelly
    Vandebosch, An
    Vansteelandt, Stijn
    De Ridder, Filip
    STATISTICS IN MEDICINE, 2019, 38 (28) : 5361 - 5375
  • [25] Conditional power calculations for clinical trials with historical controls
    Korn, Edward L.
    Freidlin, Boris
    STATISTICS IN MEDICINE, 2006, 25 (17) : 2922 - 2931
  • [26] DATA MONITORING IN CLINICAL-TRIALS - THE CASE FOR STOCHASTIC CURTAILMENT
    DAVIS, BR
    HARDY, RJ
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (09) : 1033 - 1042
  • [27] ON THE MADY MODEL FOR CLINICAL TRIALS
    Mady, Afaf M.
    JP JOURNAL OF BIOSTATISTICS, 2008, 2 (03) : 237 - 245
  • [28] ADAPTIVE RANDOMIZATION FOR CLINICAL TRIALS
    Rosenberger, William F.
    Sverdlov, Oleksandr
    Hu, Feifang
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (04) : 719 - 736
  • [29] Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes
    Zhou, Ming
    Tang, Qi
    Lang, Lixin
    Xing, Jun
    Tatsuoka, Kay
    STATISTICS IN MEDICINE, 2018, 37 (14) : 2187 - 2207
  • [30] Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial
    Hughes, Sara
    Cuffe, Robert L.
    Lieftucht, Alfons
    Nichols, W. Garrett
    PHARMACEUTICAL STATISTICS, 2009, 8 (01) : 25 - 37